Cardiovascular Toxicities of Cancer Chemotherapy
- 30 April 2013
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 40 (2), 156-167
- https://doi.org/10.1053/j.seminoncol.2013.01.004
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumabAnnals of Oncology, 2011
- Role of Biomarkers in Chemotherapy-Induced CardiotoxicityProgress in Cardiovascular Diseases, 2010
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialThe Lancet Oncology, 2010
- Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic TherapyJournal of the American College of Cardiology, 2010
- Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoringBritish Journal of Cancer, 2009
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiographyAmerican Journal Of Medicine, 1987